Shares in US biotech Cytokinetics have popped after a report that its aficamten drug improved symptoms in people with a rare and progressive form of heart disease.Treatment with the cardiac myosin inhibitor significantly improved exercise capacity in patients with obstructive hypertrophic cardiomyopathy (HCM), an inherited disorder in which the heart muscle becomes thickened and can […]
